Mylan Loses 4th Challenge Of Gilead Viread Patent
The Patent Trial and Appeal Board on Wednesday rejected a petition from Mylan Pharmaceuticals Inc. to review one of Gilead Sciences Inc.'s patents related to HIV and hepatitis drug Viread, marking...To view the full article, register now.
Already a subscriber? Click here to view full article